Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species

Ophthalmic Research

Volumn 40, Issue 1, 2007, Pages 10-15

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a   Nakamura, Kazuo ^a   Inoue, Hiroyoshi ^a   Takeuchi, Masayoshi ^b   Ueda, Seiji ^a   Okuda, Seiya ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

Advanced glycation end products; Angiotensin II; Diabetic retinopathy; Intercellular adhesion molecule 1; Monocyte chemoattractant protein 1; Olmesartan; Reactive oxygen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HYDROETHIDINE; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOKED RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; T LYMPHOCYTE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CELL ADHESION; CELLS, CULTURED; CHEMOKINE CCL2; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMIDAZOLES; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; REACTIVE OXYGEN SPECIES; SERUM ALBUMIN, BOVINE; T-LYMPHOCYTES; TETRAZOLES;

EID: 37349025554     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111152     Document Type: Article

References (28)

1. Yamagishi S, Imaizumi T: Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-2299.
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKP-DS33). Lancet 1998;352:837-853.
4. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654-11660.
5. Grandhee SK, Monnier VM: Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-11653.
6. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1998;318:1315-1321.
7. Vlassara H, Bucala R:Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996;45(suppl 3):S65-S66.
8. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM: Blockade of receptor for advanced glycation end products: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 2003;419:80-88.
9. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z: Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-1930.
10. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T: Pigment epitheliumderived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006;72:86-90.
11. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T: Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006;281:20213-20220.
12. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H: Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005;579:4265-4270.
13. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Inoue H, Takeuchi M, Choei H, Sasaki N, Kikuchi S: Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res 2003;29:75-80.
14. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-2487.
15. Fujita M, Okuda H, Tsukamoto O, Asano Y, Hirata YL, Kim J, Miyatsuka T, Takashima S, Minamino T, Tomoike H, Kitakaze M: Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:e138-e142.
16. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277:20309-20315.
17. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S: Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003;46:284-287.
18. Yamagishi S, Matsui T, Inoue H: Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp Clin Res 2005;31:227-232.
19. Carter WO, Narayanan PK, Robinson JP: Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol 1994;55:253-258.
20. Sjolie AK, Chaturvedi N: The retinal reninangiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002;16(suppl 3):S42-S46.
21. Mamputu JC, Renier G: Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 2004;75:1062-1069.
22. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999;96:10836-10841.
23. Matsumoto Y, Takahashi M, Ogata M: Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Jpn J Ophthalmol 2002;46:406-412.
24. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452.
25. Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003;52:829-837.
26. Yamagishi S, Inagaki Y, Kikuchi S: Nifedipine inhibits tumor necrosis factor-α-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidasemediated reactive oxygen species generation. Drugs Exp Clin Res 2003;29:147-152.
27. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fumaki K, Okuda S, Imaizumi T: Olmesartan blocks advanced glycation end product (AGE)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2007, May 18, E-pub ahead of print.
28. Matsubara TA, Murata TA, Wu GS, Barron EA, Rao NA: Isolation and culture of rat retinal microvessel endothelial cells using magnetic beads coated with antibodies to PECAM-1. Curr Eye Res 2000;20:1-7.